Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

NCT00039000 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: HSPPC-96 or Oncophage

Sponsor

Agenus Inc.